Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Receivables (2016 - 2025)

Ani Pharmaceuticals' Change in Receivables history spans 14 years, with the latest figure at $27.9 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 9.18% year-over-year to $27.9 million; the TTM value through Dec 2025 reached $58.5 million, up 177.56%, while the annual FY2025 figure was $58.5 million, 177.56% up from the prior year.
  • Change in Receivables for Q4 2025 was $27.9 million at Ani Pharmaceuticals, up from $27.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $27.9 million in Q4 2025 and bottomed at -$16.8 million in Q4 2023.
  • The 5-year median for Change in Receivables is $4.3 million (2022), against an average of $5.9 million.
  • The largest annual shift saw Change in Receivables soared 2333.29% in 2022 before it tumbled 253.66% in 2024.
  • A 5-year view of Change in Receivables shows it stood at -$5.4 million in 2021, then skyrocketed by 565.38% to $25.0 million in 2022, then tumbled by 167.04% to -$16.8 million in 2023, then surged by 252.2% to $25.5 million in 2024, then grew by 9.18% to $27.9 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Change in Receivables are $27.9 million (Q4 2025), $27.0 million (Q3 2025), and $5.5 million (Q2 2025).